Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Femtosecond Laser Precision Etching of Silver Layer on Silica Aerogel Surfaces.

Micromachines·2025
Same author

Effect of Laser Pulse Width on Cutting Quality and Efficiency in CFRP: Mechanism and Optimization.

Materials (Basel, Switzerland)·2025
Same author

Dual-mode CMUT structure sensor for high hydrostatic pressure measurements: conventional and collapse modes.

Microsystems & nanoengineering·2025
Same author

Establishment and verification of reference intervals for Alzheimer's disease plasma biomarkers based on evaluation of pre-analytical procedures: a multicenter study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2025
Same author

Development of a Prognostic m6A-Related lncRNA Signature and Functional Validation of FAM83A-AS1 in Lung Adenocarcinoma.

OncoTargets and therapy·2025
Same author

Assessment of Glymphatic System Function in Children With Tourette Syndrome Using Diffusion Tensor Image Analysis Along the Perivascular Space.

Biological psychiatry. Cognitive neuroscience and neuroimaging·2025

Related Experiment Video

Updated: May 8, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

A new therapy for refractory partial epilepsy: current shunt.

Limin Zhang1, Shuli Liang, Guojun Zhang

  • 1Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China; Capital Epilepsy Therapy Center, Department of Neurosurgery, First Affiliated Hospital of Chinese People's Liberation Army General Hospital, Beijing 100048, China.

Medical Hypotheses
|August 17, 2013
PubMed
Summary
This summary is machine-generated.

Researchers propose a novel "conduction" therapy for refractory epilepsy. This approach uses a current shunt with a conduction microelectrode to divert high-voltage epileptic discharges, offering a potential alternative to inhibition-based treatments.

More Related Videos

Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
05:54

Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Related Experiment Videos

Last Updated: May 8, 2026

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients
09:32

Network Analysis of Foramen Ovale Electrode Recordings in Drug-resistant Temporal Lobe Epilepsy Patients

Published on: December 18, 2016

Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
05:54

Stereo-Electro-Encephalo-Graphy (SEEG) With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Area of Science:

  • Neurology
  • Biomedical Engineering

Background:

  • Refractory epilepsy affects many patients, necessitating novel therapeutic strategies.
  • Current epilepsy treatments primarily rely on inhibition to control seizures.
  • Focal seizures originate in a localized region and spread, generating high-voltage discharges at the focus.

Purpose of the Study:

  • To investigate a novel therapeutic approach for refractory epilepsy.
  • To explore the feasibility of controlling seizures via a "conduction" mechanism.

Main Methods:

  • Proposing a current shunt using a conduction microelectrode.
  • Diverting high-voltage epileptic discharges from the seizure focus.

Main Results:

  • The study proposes a novel therapeutic strategy for epilepsy treatment.
  • This approach offers a potential alternative to existing inhibition-based therapies.

Conclusions:

  • A new
  • conduction
  • mechanism is proposed for epilepsy treatment.
  • This strategy may offer an alternative for patients with refractory partial epilepsy.